Effect of Liraglutide on Gastrointestinal Absorption of Several Drugs and Potential Influence of Liraglutide on Intragastric pH

NCT01518166 · Completed

Last updated 2026-05-28

This clinical trial tested how the diabetes medication liraglutide affects the absorption of atorvastatin in people with diabetes and healthy individuals.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 70 people

Who can join Ages 18–55 · all sexes Healthy volunteers accepted.

Timeline Started 2006-05 · est. completion 2007-04

Where 1 site · Sweden

What this study is testing ClinicalTrials.gov NCT01518166 ↗

Description as written by the study sponsor.

The trial is conducted in Europe. The aim of the trial is to investigate if there is any drug to drug interaction between liraglutide and atorvastatin (Lipitor®), lisinopril (Zestril®), griseofulvin and digoxin (Lanoxin®).

Treatments tested

liraglutide Drug

Administered as a subcutaneous injection. Initial dose 0.6 mg daily, adjusted to 1.2 mg daily in week 2 and escalated to 1.8 mg daily in week 3
placebo Drug

Administered as a subcutaneous injection. Given as daily volume of 100 mcl, 200 mcl and 300 mcl respectively
atorvastatin Drug

One single dose of 40 mg. Tablet
lisinopril Drug

One single dose of 20 mg. Tablet
griseofulvin Drug

One single dose of 500 mg. Tablet
digoxin Drug

One single dose of 1 mg. Tablet

Main thing measured	Area under the curve of atorvastatin
Sponsor	Novo Nordisk A/S
Conditions studied	Diabetes, Healthy
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01518166 ↗